Detalles de la búsqueda
1.
Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
J Biol Chem
; 287(33): 28087-98, 2012 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-22730329
2.
Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model.
Invest New Drugs
; 30(3): 936-49, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21360050
3.
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.
Mol Cancer Ther
; 19(2): 460-467, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31645440
4.
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.
Mol Cancer Ther
; 18(12): 2207-2219, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31530649
5.
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.
Cancer Discov
; 9(2): 248-263, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30373917
6.
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.
Clin Cancer Res
; 23(18): 5547-5560, 2017 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28611205
7.
Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.
Cancer Discov
; 6(3): 300-15, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26732095
8.
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Cancer Cell
; 28(3): 384-98, 2015 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26343583
9.
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
J Med Chem
; 58(10): 4165-79, 2015 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-25965804
10.
Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.
J Med Chem
; 47(16): 3934-7, 2004 Jul 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-15267232
11.
A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.
Mol Cancer Ther
; 10(11): 2200-10, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-21900693
12.
Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
Bioorg Med Chem Lett
; 16(24): 6293-7, 2006 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17005393
13.
Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands.
Bioorg Med Chem Lett
; 16(24): 6328-33, 2006 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17005394
14.
The development of potent and selective bisarylmaleimide GSK3 inhibitors.
Bioorg Med Chem Lett
; 15(4): 899-903, 2005 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15686883
15.
Imidazopyrimidines, potent inhibitors of p38 MAP kinase.
Bioorg Med Chem Lett
; 13(3): 347-50, 2003 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-12565927
Resultados
1 -
15
de 15
1
Próxima >
>>